Navigation Links
RVX-208 Data Demonstrates Increase in Functional HDL Particles

Prebeta-HDL generation and improved HDL functionality are distinguishing


TSX Exchange Symbol: RVX

NEW ORLEANS, LA, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled "Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials" was presented by Dr. Jacques Genest.

Dr. Jacques Genest, MD, Director of the Division of Cardiology at McGill University Health Centre/Royal Victoria Hospital said, "We continue to be excited about the data that is being generated for RVX-208. It is important that our colleagues have access to this promising data which is why we have presented at this prominent conference. Resverlogix's novel drug demonstrated the ability to increase the production of ApoA-I and functional HDL. Notably we saw increases in prebeta-HDL particles, which improve HDL's ability to mediate cholesterol efflux."

"Today we presented interesting and consistent data from African Green monkey studies and our Phase 1a human clinical trial at the AHA," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Medical Affairs of Resverlogix. "The pharmacodynamic data from human healthy volunteers of which the majority had low HDL demonstrated that we have seen significant increases in ApoA-I production and HDL functionality, consistent with previous findings in the African Green monkey studies. Further investigation of the effect of RVX-208 on the HDL metabolic pathway is ongoing in humans and animals to establish the mechanisms of action and therapeutic potential in treating atherosclerotic cardiovascular disease."

During the presentation Dr. Genest reported that in an African Green monkey study treatment with RVX-208 resulted in a highly significant increase in the average of serum ApoA-I and HDL-C levels (57% and 92%, respectively). It was noted that RVX-208 treatment modified the distribution of HDL particle size causing a significant increase in prebeta-HDL and the larger alpha-HDL particles. The ability of serum to promote cholesterol efflux via ABCA1, ABCG1 or SR-BI-dependent pathways in a cell culture model was significantly increased by RVX-208.

Data was also presented for Resverlogix's Phase 1a safety and pharmacokinetic human study which was comprised of a total of 80 subjects. RVX-208 was found to be well tolerated and had good oral absorption meeting the objectives of safety and pharmacokinetics.

In the multiple ascending dose arms, 24 participants were randomly assigned to 3 cohorts of 8 healthy volunteers (6 active and 2 placebo), and received oral administration of RVX-208 at 2, 3 and 8 mg/kg/day or placebo for 7 days. ApoA-I, HDL-C, HDL particle size distribution and ABCA1-dependent cholesterol efflux were assessed on day 1 (pre-dose) and day 7. Following administration for 7 days, treatment with RVX-208 increased the change for ApoA-I by 11% (P=0.03) in treated subjects compared with placebo. Interestingly, the corresponding prebeta-HDL change was 42% (P=0.007) in the actively treated group compared to control. Furthermore, sera from subjects were assessed for ABCA1 mediated cholesterol efflux as a predictive marker for reverse cholesterol transport. Again, ABCA1-dependent cholesterol efflux change increased by 10% (P=0.03) and was found to correlate with increased prebeta-HDL. Taken together these data demonstrate the ability of RVX-208 to generate prebeta-HDL, improve HDL functionality, which clearly differentiates RVX-208 from other HDL therapies, and making it the first of a new drug class.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. Apolipoprotein A-I (ApoA-I), the main component of high-density lipoprotein (HDL) represent the bodies natural defense system against atherosclerosis by mediating reverse cholesterol transport, i.e. transport of peripheral cholesterol including that of the vessel wall to the liver for processing. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise prebeta-HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT).

RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis. Major constituents of RCT include acceptors such as high-density lipoprotein (HDL) and apolipoprotein A-I (ApoA-I). A critical part of RCT is cholesterol efflux, in which accumulated cholesterol is removed from macrophages.

The American Heart Association estimates that almost 80 million American Adults have one or more types of cardiovascular disease. CVD remains the number one killer of developed nations. Nearly 2400 Americans die each day from cardiovascular disease.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. RVX-208 Exploratory Study Illustrates Early Potential for Alzheimers Disease
2. International Steering Committee for RVX-208 IVUS Trial Formed
3. Phase 1b/2a Program Commences for RVX-208
4. Industry Leaders Select Resverlogixs RVX-208
5. Dosing for RVX-208 Phase 1a Clinical Study Completed
6. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
7. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
8. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
9. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
10. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
11. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
Post Your Comments:
(Date:10/8/2015)... Celemics, a global pioneer of personalized medicine ... market with the establishment of Celemics America, Inc. ... Europe , has secured itself in the global ... sample preparation for DNA sequencing and genetic testing.  Next ... genetic testing more accurately, quickly, and cost effectively than ...
(Date:10/8/2015)... 8, 2015  The ALS Association, in partnership with ... Challenge to revolutionize communication technology solutions for people living ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative ... and the spinal cord. Eventually, people with ALS lose ... often leads to total paralysis and death within two ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS ... license agreement to develop and commercialize intellectual property rights belonging to The University ... February 2009, and affords exclusive worldwide rights to intellectual property based on use ...
(Date:10/7/2015)... Dallas-Fort Worth, Texas (PRWEB) , ... October 07, ... ... Stem Cell Institute ( ) will present a public educational seminar on ... diseases on Saturday, October 10th from 1:00 pm – 3:00 pm at the ...
Breaking Biology Technology:
... Sciences, Inc. (Nasdaq: CALP ) today announced that ... "Innovation for Experimentation" to be held June 17, 2009 at ... Breakout Session from 2:30 - 4:00 p.m. EDT. , ... by Kevin Hrusovsky, President and CEO, as well as several ...
... BEIJING, June 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE ... in China, announced today that it,begins the production of a vaccine ... CDC and was delivered to the company on June 8, 2009. ... CEO of Sinovac, commented, ,In,the midst of a global outbreak and ...
... to Help Ease Venipuncture Process , , UnitedPharma ... , COLD SPRING HARBOR, N.Y., June 8 ... Services for America,s Blood Centers (GSABC) bringing the AccuVein ... to GSABC member blood centers. Under the agreement, ...
Cached Biology Technology:
(Date:9/10/2015)... , Sept. 10, 2015 This report ... wearable technology products today, and emerging sensor types that ... risen through the peak of the wearable technology hype ... slide to disillusionment. The common feature with all of ... key enabler for their most useful functions. Sensors collect ...
(Date:9/10/2015)... Sept. 10, 2015 Report Details ... quite delivered upon previous expectations of revenues, consumer adoption ... breakthrough year in which wearables begin to achieve that ... of the main reasons is the entrance of Apple ... the SmartWatches market, but the overall size of the ...
(Date:9/10/2015)... 10, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that the ... Touch of Modern, will feature the Wocket® smart wallet ... . Touch Of Modern is ... lifestyle products to its 7.2 million members. Customers are ...
Breaking Biology News(10 mins):
... massive changes to the Earth's landscape , The ice ages ... happening below the ice in the oceans? , Research by ... destruction as whole communities of animals were wiped out by ... it has been thought that these ecosystems somehow dodged extinction ...
... at the Naval Research Laboratory's Marine Meteorology Division ... Monterey Bay Aquarium Research Institute and the National ... of a phenomenon known as the "milky sea." ... ship-based account. This research was published in the ...
... Wright Brothers' first biplanes to monoplanes was an inadvertent ... say two dino flight experts. , According to ... a small early Chinese dinosaur called Microraptor gui used ... to tree in the early Cretaceous. Among the evidence ...
Cached Biology News: